Stephens & Co. Maintains Overweight on Veracyte, Lowers Price Target to $40
Benzinga Newsdesk 51 minutes ago
Analyst RatingsNewsPrice Target
Stephens & Co. analyst Mason Carrico maintains Veracyte (NASDAQ:VCYT) with a Overweight and lowers the price target from $55 to $40.
Stephens & Co. analyst Mason Carrico maintains Veracyte (NASDAQ:VCYT) with a Overweight and lowers the price target from $55 to $40.